Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

      Interim Management Statement - 3 months to 30 June 2014 (unaudited)      

Worldwide Healthcare Trust PLC invests worldwide in a diversified portfolio of 
shares in pharmaceutical and biotechnology companies and related securities in 
 the healthcare sector with the objective of achieving a high level of capital 
                                    growth.                                    

During the 3 month period ended 30 June 2014 the Company's fully diluted net
asset value per share total return was +3.3% and the Company's share price
total return was +0.8%. The Company's benchmark, the MSCI World Health Care
Index measured in sterling terms on a total return basis rose by 2.2% in the
same period. During the period, exposure to Europe increased while the
portfolio's exposure to Asian and Emerging Markets was reduced. Exposure to
North America remained unchanged. From the period-end to 28 July 2014, the
Company's fully diluted net asset value per share total return was 0.9% and the
Company's share price total return was 1.3%. The Company's benchmark, the MSCI
World Health Care Index measured in sterling terms on a total return basis rose
by 1.0% in the same period.

During the period under review and to the date of this report 369,770 new
shares were issued as a result of holders of subscription shares exercising
their subscription rights. The exercise price is 699p and the next and final
subscription date is 31 July 2014. Instructions to exercise subscription rights
are required to be received by the Company's Registrars by the close of
business in the UK on 31 July 2014.

No shares were repurchased by the Company during the three-month period and to
the date of this report and no shares are currently held by the Company in
treasury.

The Company paid a second interim dividend of 8.0p per share which, together
with the first interim dividend of 7.0p per share already paid, made a total
dividend for the year ended 31 March 2014 of 15.0p per share (2013:16.5p per
share). The second interim dividend was paid on 4 July 2014 to ordinary
shareholders on the register of members on 6 June 2014. The associated
ex-dividend date was 4 June 2014.

At the Company's Annual General Meeting, held on 14 July 2014, all of the
resolutions, including the approval of the continuance of the Company as an
investment trust for a further period of five years, were passed.

In accordance with and in order to comply with the requirements of the
Alternative Investment Fund Managers Directive, the Directors of the Company
have appointed Frostrow Capital LLP as the designated Alternative Investment
Fund Manager for the Company.

The Company has also appointed J.P. Morgan Europe Limited as its depositary and
J.P. Morgan Clearing Corp. to provide prime brokerage services to the Company
replacing Goldman Sachs who previously acted as custodian and prime broker to
the Company.

OrbiMed Capital LLC continues to be responsible for the management of the
Company's portfolio of investments.

Trust Characteristics

                            30 June 2014             31 March 2014             
                                                                               
Number of holdings          64                       63                        
                                                                               
Net assets (£m)             653.8                    636.2                     
                                                                               
Net yield                   1.2%                     1.3%                      
                                                                               
Gearing (AIC basis)         10%                      12%                       
                                                                               
Share price (p)             1303.00                  1301.00                   
                                                                               
NAV (p) undiluted           1397.81                  1365.74                   
                                                                               
NAV (p) diluted: sub shares 1376.17                  1339.97                   
                                                                               
Discount (undiluted)        6.8%                     4.7%                      
                                                                               
Discount diluted: sub       5.3%                     2.9%                      
shares                                                                         
                                                                               
Subscription share price    602.50                   595.50                    
(p)                                                                            

Source: Frostrow Capital LLP


10 Largest Investments

Name                       % of                      % of                      
                           portfolio                 portfolio                 
                           at 30 June 2014           at 31 March 2014          
                                                                               
Roche                      6.4                       6.8                       
                                                                               
HCA                        3.8                       3.7                       
                                                                               
Bristol-Myers Squibb       3.7                       3.3                       
                                                                               
Abbvie                     3.6                       2.8                       
                                                                               
Mylan                      3.6                       3.6                       
                                                                               
Merck & Co                 3.5                       3.7                       
                                                                               
Regeneron Pharmaceuticals  3.1                       3.5                       
                                                                               
Amgen                      3.0                       3.3                       
                                                                               
Biogen Idec                2.9                       3.0                       
                                                                               
Actelion                   2.8                       2.2                       
                                                                               
                           36.4                      35.9                      

Source: Frostrow Capital LLP


Sector Analysis

                           % of                      % of                      
                           portfolio                 portfolio                 
                           at 30 June 2014           at 31 March 2014          
                                                                               
Large capitalisation       72.3                      74.1                      
                                                                               
Small capitalisation       27.7                      25.9                      
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP


Geographical Analysis

                           % of                      % of                      
                           portfolio                 portfolio                 
                           at 30 June 2014           at 31 March 2014          
                                                                               
North America              73.7                      73.6                      
                                                                               
Europe                     15.6                      11.4                      
                                                                               
Emerging Markets           6.1                       8.5                       
                                                                               
Asia                       4.6                       6.5                       
                                                                               
Total                      100.0                     100.0                     

Source: Frostrow Capital LLP


Total Return Performance

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +0.8            +25.8           +82.2           +168.6         
                                                                               
NAV Fully       +3.3            +27.4           +76.6           +165.7         
diluted                                                                        
                                                                               
Benchmark*      +2.2            +14.2           +61.8           +136.2         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Bloomberg and Thomson Reuters

* With effect from 1 October 2010, the performance of the Company is measured
against the MSCI World Health Care Index measured on a total return basis in
sterling terms. Prior to this date, performance was measured against the
Datastream World Pharmaceutical and Biotechnology Index on a total return basis
in sterling terms. Historic data, therefore, consists of a blended figure
containing both indices.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

Identification Codes:

Ordinary Shares
SEDOL- 0338530
ISIN - GB0003385308
Bloomberg - WWH LN
EPIC - WWH

Subscription Shares
SEDOL - B3VMCB0
ISIN - GB00B3VMCB07
Bloomberg - WWHS LN


For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP
Company Secretary
30 July 2014